Lee Ainslie Viridian Therapeutics, Inc.\De Transaction History
Maverick Capital LTD
- $5.17 Billion
- Q4 2024
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Maverick Capital LTD holds 2,053,906 shares of VRDN stock, worth $34.2 Million. This represents 0.76% of its overall portfolio holdings.
Number of Shares
2,053,906
Previous 1,997,153
2.84%
Holding current value
$34.2 Million
Previous $45.4 Million
13.34%
% of portfolio
0.76%
Previous 0.94%
Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$79.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$76.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$75.3 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$64.6 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$58.7 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $664M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...